Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial
To the editor: Hand-foot skin reaction (HFSR), characterized by skin abnormalities on palmoplantar surfaces, has an overall incidence of about 35% upon vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) treatment.1 Zinc, which plays a role in maintaining skin health, may be implicated in the pathogenesis of HFSR.2 Zinc deficiency has been shown to associate with dermatological toxicities of epidermal growth factor receptor (EGFR)-TKI.3, 4 Regorafenib, an oral multi-kinase inhibitor targeting VEGFR 1 –3, PDGFR, cKIT, BRAF, and RET1, is approved for the treatment of metastatic colorectal cancer (mCRC) but commonly causes HFSR.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Wen-Kuan Huang, Hung-Chih Hsu, Tsai-Sheng Yang, Chun-Wei Lu, Yi-Ru Pan, Chiao-En Wu, Wen-Hung Chung, Shuen-Iu Hung, Chun-Nan Yeh Tags: Current Perspective Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | Dermatology | Oral Cancer | Skin | Toxicology | Zinc